Summary of the Conference Call for Tigermed (泰格医药) Industry Overview - The clinical CRO (Contract Research Organization) industry is expected to maintain a double-digit growth rate of 10%-15% during the new recovery cycle after experiencing a slowdown in growth from 2023 to 2024, driven by policy support, increased local investment from multinational pharmaceutical companies, and record-high license-out transactions by domestic biopharmaceutical companies [2][5][13]. Company Positioning - Tigermed, as the leading player in China's clinical CRO market, has increased its market share from 8% in 2019 to 13% in 2023, benefiting from the strong performance of top-tier companies and the development of the SMO (Site Management Organization) industry [2][5]. - The company is actively expanding its international presence in regions such as Asia-Pacific, Europe, and the Americas, and has acquired a Japanese imaging analysis company to enhance its capabilities [2][6]. Key Trends and Changes - The supply side of the clinical CRO industry is showing signs of consolidation, with the number of sponsors decreasing by approximately 64% and the number of clinical trials declining by 72% compared to the peak in 2022 [3][7]. - Despite a relatively flat primary market in recent years, the demand for innovative drugs and equity cooperation is gradually filling the financing gap, leading to more opportunities for clinical CROs [3][13]. Impact of Multinational Companies - Multinational pharmaceutical companies are becoming significant payers in the clinical CRO industry, with 24% of phase III clinical trials in 2024 being sponsored by these companies, and the proportion of projects conducted by local CROs increasing from 23% in 2020 to 32% in 2024 [8][7]. License-Out Transactions - License-out transactions in the Chinese pharmaceutical sector have grown rapidly, with 94 transactions totaling $51.9 billion in 2024, primarily involving the U.S. as the main recipient [9]. Technological Advancements - Tigermed is embracing AI technology and remote intelligent clinical solutions to improve data quality, efficiency, and reduce costs, which is expected to enhance profitability [4][17]. Financial Performance - Tigermed's revenue and profit growth from 2023 to 2024 have been impacted by declining clinical operation order prices and some order cancellations, but the overall order prices are expected to stabilize in 2025 [28][33]. - New order growth remains positive, with a 20% year-on-year increase in new orders in the first quarter of 2025 [29]. Future Outlook - The company is well-positioned to benefit from the recovery of domestic demand and the ongoing trend of Chinese innovative drugs going global, which will drive incremental demand for Tigermed's services [18][33]. - The focus on emerging treatment areas such as cell and gene therapy (CGT) and the expansion of its service capabilities through acquisitions are expected to support sustainable growth [25][20]. Conclusion - Tigermed's strategic initiatives, including international expansion, technological innovation, and a strong market position, are expected to drive its growth in the recovering clinical CRO industry, with optimism for future performance as market conditions improve [14][33].

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 1.1816 million shares at an average price of HKD 55.9087 per share, totaling approximately HKD 66.0617 million [1] - After the purchase, E Fund's total shareholding in Tiger Med increased to 13.8033 million shares, raising its ownership percentage from 10.25% to 11.21% [1][2]

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has increased its stake in Tiger Medical (03347) by acquiring 1.1816 million shares at a price of HKD 55.9087 per share, totaling approximately HKD 66.0617 million [1] - After the increase, E Fund's total shareholding in Tiger Medical is now 13.8033 million shares, representing an ownership percentage of 11.21% [1]

Group 1 - E Fund Management Co., Ltd. increased its stake in Tiger Medical (300347) by 118.16 thousand shares at a price of 55.9087 HKD per share, totaling approximately 66.06 million HKD [1] - After the increase, the total number of shares held by E Fund is 13.8033 million, representing a holding percentage of 11.21% [1]

智通财经APP获悉，香港联交所最新数据显示，7月29日，易方达基金管理有限公司增持泰格医药 (03347)118.16万股，每股作价55.9087港元，总金额约为6606.17万港元。增持后最新持股数目为1380.33 万股，持股比例为11.21%。 ...

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Investment Rating - The investment rating for the CXO industry is "Outperform the Market" [1] Core Insights - The CXO index has increased by over 50% in the past year due to the easing of geopolitical risks, recovery in investment, and the digestion of high pandemic baselines [2] - Chinese CXO companies are analyzed from short-term, medium-term, and long-term perspectives to understand their global competitiveness [2] - Major players in the large molecule CDMO sector include WuXi Biologics and WuXi AppTec, with over 70% of their revenue coming from overseas [2] - The small molecule CDMO sector shows strong recovery in domestic companies, with significant order growth and a favorable competitive landscape [2] - Clinical and preclinical CROs are currently in an adjustment phase, with domestic order prices stabilizing but showing no significant recovery [2] Summary by Sections Large Molecule CDMO - Short-term performance shows high growth with competition from Japan, South Korea, and Europe [2] - Medium-term order growth is led by South Korean companies like Samsung Biologics, indicating intense competition for Chinese firms [2] - Long-term capital expenditures remain high, reflecting confidence in future demand [2] Small Molecule CDMO - Domestic companies are recovering from pandemic-related performance dips, with overall growth expected in 2025 [2] - Order growth is robust, with WuXi AppTec's orders increasing by 47% year-on-year by the end of 2024 [2] - Long-term capital expenditures show divergence, with some leaders like WuXi AppTec expected to continue increasing investments [2] Clinical/Preclinical CRO - Both domestic and international CROs are in an adjustment period, with 2022-2023 investment cooling reflected in 2024 performance [2] - Medium-term order volumes and values are beginning to show growth, while international orders remain stable [2] - Long-term capital expenditures vary among companies, indicating potential supply-demand mismatches in the short term [2] Emerging Business Opportunities - Rapid development in new molecular businesses such as peptides and oligonucleotides is expected to open up growth opportunities in the CXO sector [3] - Generic drug CROs are actively pursuing innovative transformations to seek new growth points [3]

Group 1: Macro and Strategy Insights - The macro view for August indicates a stable policy environment with an upward shift in risk appetite, suggesting that industrial growth will remain a key theme [7] - The strategy outlook highlights an "extension of offensive trends" in the market, with a recommendation to maintain positions and selectively increase holdings as the A-share market shows a bullish trend [8] - The quantitative perspective suggests breaking the deflationary spiral, with expectations for a cyclical upswing in the market [9] Group 2: Selected Stocks for August - The selected stocks for August include China Pacific Insurance (non-bank), China Shipbuilding Industry (military), Shanghai Yanpu (large manufacturing), Weilan Lithium (electric new energy), Wanjun Technology (computer), Guomai Culture (media), Baiwei Storage (consumer electronics), Huaxi Nonferrous Metals (non-ferrous), Sun Paper (light industry), and Tigermed (pharmaceutical) [11] - China Pacific Insurance is positioned as a leading insurance company with a strong background, expected to benefit from its transformation and increase in new business value [12] - China Shipbuilding Industry is identified as a leader in naval defense, benefiting from advancements in deep-sea technology and a growing market for underwater monitoring systems [17] - Shanghai Yanpu is noted for its potential in the seating market, with a platform transformation expected to enhance performance and market share [20] - Weilan Lithium is recognized for its robust main business and potential for valuation upgrades due to new product developments [25] - Wanjun Technology is highlighted for its long-standing expertise in creative software, with AI product commercialization expected to accelerate growth [28] - Guomai Culture is anticipated to benefit from the release of its animated film "The Stars of the Three Kingdoms," which is expected to drive revenue [32] - Baiwei Storage is positioned to benefit from the upward cycle in the storage industry, with a focus on advanced packaging technology [38] - Huaxi Nonferrous Metals is expected to see price increases in tin and antimony, driven by strong demand and limited supply [43] - Sun Paper is projected to benefit from industry stabilization and cost advantages from its integrated operations [50] - Tigermed is positioned to gain from the growing demand for clinical CRO services as the innovative drug sector expands [55]

格隆汇7月31日丨根据联交所最新权益披露资料显示，2025年7月24日，泰格医药(03347.HK)遭易方达基金管理有限公司在场内以每股均价50.0506港元减持 27.31万股，涉资约1366.88万港元。 减持后，易方达基金管理有限公司最新持股数目为1351.47万股，持股比例由11.20%下降至10.98%。 | 股份代號: | | --- | | 上市法國名稱: | | 日期 (日 / 月 / 年 | 追加内容 本文作者可以追加内容哦 ! | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述 * 註 | 有投票權股 日 / 月 / 年) | | | | | | | | 解) | 份百分比 | | | | | | | | | ( % ) | | CS20250729E00287 | 易方达基金管理有限公司 | 1201(L) | ...

| 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | （請參閱上述 * 註 有投票權股 (日 / 月 / 年） | | | | | | | | 解) 份百分比 | | | | | | | | ( % ) | | CS20250729E00287 | 易方达基金管理有限公司 | 1201(L) | | 273,100(L | HKD 50.0506 | 13,514,700(L) 10.98(L)24/07/2025 | 减持后，易方达基金管理有限公司最新持股数目为1351.47万股，持股比例由11.20%下降至10.98%。 | 股份代號: | 03347 | | --- | --- | | 上市法國名稱: | 杭州泰格醫藥科技股份有 | | 日期 (日 / 月 / 年): | 30/06/2025 - 31/07/2025 | 格隆汇7月31日丨根据联交所最新权益 ...